Neosinus enters into Strategic Partnership with Hobson Institute to Collaborate on Improving Breathing Health
RALEIGH, March 30, 2021 /PUBLIC RELEASE/ -- Neosinus Health, an emerging Drug Development Platform Company, which has developed a best-in-class configurable intranasal delivery platform has partnered with Hobson Institute to collaborate on several fronts to improve breathing health on a global basis.
Considering that the majority of people suffer from some form of breathing disorder or experience breathing-related symptoms such as asthma, snoring, fatigue, sleep apnea, or digestive issues, this collaboration represents a major advancement in helping people restore their breathing. By merging the revolutionary Neosinus nasal rinsing device with industry leading myofunctional therapies offered by the Hobson Institute, the therapy-device combination will deliver a best-in-class wellness offering for health providers and their patients.
Beyond the delivery of the therapy-device combination, the collaboration will also focus on educating people about the role of the respiratory region of the nose in managing the function and quality of breathing. The partnership also accelerates market access to the expanding Neosinus line of consumer products, starting with their novel nasal rinse device, which was developed for the treatment of sinus pressure, allergies, nasal congestion, and to improve overall sinus health and breathing. As demonstrated by market feedback since the recent launch of the Neosinus Rinse Kit, the device delivers a targeted rinse experience like no other product on the market, so the expanded market access will be a win for patients and healthcare providers.
New Design and Rinse Experience: Unlike any other intranasal delivery product on the market, the device is designed based on the anatomy of the nose. It features a curved nozzle with directional control for a targeted rinse experience. This allows the device to bypass nasal barriers and directs the fluid towards areas that benefit from rinsing and away from areas that cause discomfort.
The nasal rinse device will not block the opening of the nose or force the fluid out the opposite nostril, which means that all allergens and bacteria are properly flushed out of the nose and not pushed towards the back of the throat and into the body. As noted by a recent usage study conducted by Neosinus, the effectiveness of the product and improved overall experience for patients has resulted in medical compliance in terms of product usage near 90%. As highlighted by the global problem of medication adherence being less than 50%, healthcare providers recognize that outcomes will not improve unless usage compliance improves, so the level of compliance achieved by the Neosinus device represents a major medical step forward.
“The synergy and value of a partnership with Hobson Institute was evident on the first call, where it was clear that both companies are focused on the importance of proper breathing to enhance the quality of life for people,” said Don Turner, Chairman and CEO of Neosinus Health. “We continue to receive extremely positive feedback from doctors and patients on the gentle and effective experience with our device. Our product has clinically shown to be 10X more effective at reaching the critical areas of the nasal anatomy that contribute to breathing, so combining our device with a leading myofunctional therapy program offered by Hobson Institute was a no brainer.”
Dr. Jennifer Hobson, Founder of Hobson Institute, said “ The Hobson Institute is excited to be in partnership with Neosinus and the product is now included in our breathing re-training online programs that train nasal breathing. It is a great product that allows the nose to be cleaned in the most efficient and comfortable way. Neosinus is in sync with the goals that we have for our patients that suffer from poor breathing habits. We strive to improve the nasal breathing potential for our clients and patients.”
About Neosinus Health
Neosinus Health Inc. is a Raleigh-based drug development platform company that has commercialized a patented and configurable intranasal drug delivery platform for targeted therapy. The core platform is designed to optimize the delivery of medications to essential drug pathways and overcome physiological barriers like no other device. The company has commercialized a platform that will transform the delivery of drugs for neurological and psychiatric disorders, respiratory illnesses, viral infections, and more through strategic out-licensing partnerships and internal clinical development programs. The company is playing a leadership role in advancing a new and innovative class of brain drugs and psychedelics that will address the largest global health burden and finally deliver new therapies that have been unattainable for many decades.
About Hobson Institute
The Hobson Institute is a distinctive institution focusing on head, neck and breathing health. We are dedicated to training and educating proper nasal breathing and how it positively counteracts the symptoms of asthma, attention deficit disorders, anxiety, chronic fatigue, sleep apnea, tongue-tie and tongue thrust, lisping, improper swallowing, digestive issues and more. The Hobson Institute implements programming and media through events, podcasts, training curriculums and clinics geared toward transforming head, neck and breathing health. Our mission is dedicated to assisting healthcare professionals as well as those who suffer from breathing disorders.
Neosinus Health Media Contact: PR@neosinus.com
For more information on Neosinus Health: www.neosinus.com
For more information on Hobson Institute: www.hobsoninstitute.com
Neosinus enters into Strategic Partnership with DailyBreath to Collaborate on Improving Allergy and Asthma Management
